Figure 5.

Jzu 17 inhibits VEGFR‐2‐mediated signalling in HUVECs. HUVECs were treated with indicated concentrations of Jzu 17 for 30 min, followed by the stimulation with VEGF‐A (25 ng·ml⁻¹) for another 5 (VEGFR‐2) or 20 (FAK, Src, Akt and ERK1/2) min. Phosphorylation status of VEGFR‐2 (a), FAK (b), Src (c), Akt (d), and ERK1/2 (e) were determined by immunoblotting. The compiled results of VEGFR‐2 Tyr¹¹⁷⁵ (a), Src Tyr⁴¹⁶ (b), FAK Tyr³⁹⁷ (c), Akt Ser⁴⁷³ (d), and ERK1/2 Thr²⁰²/Tyr²⁰⁴ (e) phosphorylations are shown. Each column represents the mean ± SEM of six independent experiments. # P < .05, compared with the control group; *P < .05, significantly different from VEGF‐A alone; Kruskal–Wallis test